Drugs / CPV-104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07483827 | Jun 2025 → Jun 2026 overdue | complement 3 glomerulopathy | eleva GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPV-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483827 ↗ |
| Route | Intravenous | “All treatments will be administered intravenously by a healthcare professional (HCP).” NCT07483827 ↗ |